Core Viewpoint - Tong Ren Tang has demonstrated resilience and growth in a complex macroeconomic environment, achieving steady revenue growth and maintaining its position as a leading traditional Chinese medicine enterprise [2]. Financial Performance - In 2024, Tong Ren Tang achieved operating revenue of 18.597 billion yuan, representing a year-on-year increase of 4.12% [2]. - The net profit attributable to shareholders of the listed company saw a decline, but the company managed to maintain growth in operating revenue and net assets through targeted strategies [2]. - The total cash dividend proposed for 2024 is 1.371 billion yuan, accounting for 89.86% of the net profit attributable to shareholders, reflecting the company's commitment to shareholder returns [3]. Marketing and Innovation - The company has implemented marketing reforms by increasing retail outlets, integrating online and offline operations, and expanding medical terminal businesses to enhance market competitiveness [2]. - Tong Ren Tang has increased investment in technological innovation to modernize traditional Chinese medicine, laying a solid foundation for long-term development [2][4]. Governance and Communication - The company continues to improve internal management systems and emphasizes the supervisory role of independent directors to ensure scientific and standardized decision-making [3]. - Management actively engages with investors through regular performance briefings and investor communication events to build trust and confidence [3]. Future Development Strategy - Tong Ren Tang plans to focus on high-quality development in the health sector, enhancing market share and brand influence through marketing reforms and brand building [4]. - The company aims to increase research and development investments, promoting the integration of traditional Chinese medicine with modern technology [4]. - Plans include expanding overseas markets and enhancing international brand influence through partnerships with global pharmaceutical companies [4]. Social Responsibility - The company is committed to sustainable development, increasing environmental investments, and engaging in public welfare activities to support the inheritance and development of traditional Chinese medicine [5]. - Future initiatives will focus on accelerating medical industrial upgrades and digital transformation to enhance productivity [5].

今年以来,受美国所谓"对等关税"等 政策影响,全球贸易不确定性明显增多,经 济全球化遭遇严重挑战。新形势下,山东外 贸企业加速实行内外贸一体化发展战略,加 快拓展国内市场。 外贸一线调研行 9 7 15 法 晚安 扫码阅读全文 内贸"新兵"要有长远眼光 "与其将开拓国内市场作为应对危机的被动选择，不如视作转型升级的战略机遇" 今年以来，受美国所谓"对等关税"等政策影响，全球贸易不确定性明显增多，经济全球化遭遇严重挑 战。新形势下，山东外贸企业加速实行内外贸一体化发展战略，加快拓展国内市场。外贸企业做内贸， 市场前景如何？记者赴外贸一线寻找答案。 危中孕机，国内市场前景广阔 数据显示，2024年中国社会消费品零售总额突破48.8万亿元，相当于对美出口额的10倍有余。因此，尽 管当前我国外贸企业受到冲击，但出口转内销的条件比较成熟。 "我们以前只做国外生意，今年开始做国内市场。"5月1日，济南大明湖畔，记者在2025山东省外贸优品 购物季进景区活动现场，见到了刚刚参加完广交会的吹岚智能科技（山东）有限公司负责人张道财。这 家企业主要生产擦玻璃机器人等清洁类机器人，产品出口欧盟、美国、日本、韩国等市场。 张道财介绍 ...

新华社南京5月6日电 题：起底新型保健品电话销售诈骗 新华社记者朱国亮 警惕一种新型保健品电话销售诈骗——诈骗犯罪嫌疑人冒充正规保健品公司客服、医疗专家，通过电话 为购买过保健品的中老年人诊疗，一番忽悠后高价推销药品。 江苏省无锡市滨湖区人民检察院正在办理的一起案件，揭开了该类诈骗黑色链条。 众多中老年人被骗 "您好！是徐大爷吗？"2022年5月，无锡市滨湖区85岁的徐大爷接到一家保健品销售企业"健康指导老 师"的电话。因为买过该企业的药酒，效果还不错，加之对方能报出自己的姓名、住址，徐大爷便放松 了警惕。 对方主动询问徐大爷使用药酒效果如何、满意与否，继而通知徐大爷一个"好消息"：知名专家"李老 师"当天将抽时间给全国20名患者电话会诊，若徐大爷同意，她可替徐大爷报名。徐大爷同意后，对方 便告知他，稍后"李老师"会给徐大爷打电话。 过了一会儿，"李老师"打来电话，很热情地关心徐大爷的病情。一阵"电话会诊"之后，"李老师"向徐大 爷推销三种药，称可治疗高血压和关节问题，保证药到病除。 "我常收看电视台这位中医专家的节目，一听'老师'声音很熟悉也就没有怀疑，最后还价到2500元成 交。药是用货到付款寄递过来的。 ...